TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) Investor Files Lawsuit Over Alleged Wrongdoing In Porposed Acquisition

  • If you purchased shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) and currently hold any of those NASDAQ:AVNR shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Avanir Pharmaceuticals Inc
Security
NASDAQ: AVNR

Case Name
Avanir Pharmaceuticals Deal Case 12/04/2014
Type of Lawsuit
Mergers and Acquisition
You must register or login to receive notifications.

Click here to subscribe to Avanir Pharmaceuticals Inc.
Summary

December 5, 2014 (Shareholders Foundation) - An investor, who currently holds shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR filed a lawsuit in effort to halt the proposed takeover of Avanir Pharmaceuticals Inc by Otsuka Pharmaceutical Co for $17.00 per share.
The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:AVNR stockholders by agreeing to sell Avanir Pharmaceuticals Inc too cheaply via an unfair process to Otsuka Pharmaceutical Co

On December 2, 2014, Avanir Pharmaceuticals Inc (NASDAQ:AVNR) announced that it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire Avanir Pharmaceuticals Inc (NASDAQ:AVNR) for $17.00 per share in cash.

However, the plaintiff claims that the takeover undervalues Avanir Pharmaceuticals Inc. Indeed, at least one analyst has set the high target price for NASDAQ:ANVR shares at $21.00 per share. Furthermore, Avanir Pharmaceuticals’ Total Revenue rose from $2.90 million for the 12 months period that ended on Sept. 30, 2010 to $75.37 million for the 12 months period that ended on Sept. 30, 2013. Shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) grew from $0.29 per share in November 2008 to as high as $15.30 per share in late November 2014. In addition, the plaintiff alleges that the process is also unfair to Avanir Pharmaceuticals Inc.

On December 4, 2014, NASDAQ:AVNR shares closed at $16.96 per share.